Sy­ros' stock up al­most 30% af­ter pos­i­tive ear­ly PhII da­ta for blood can­cer drug

Sy­ros Phar­ma­ceu­ti­cals’ drug can­di­date for hema­to­log­i­cal ma­lig­nan­cies saw an in­creased com­plete re­sponse rate ver­sus stan­dard of care in a mid-stage acute myeloid leukemia tri­al, mark­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER